Date published: 2026-1-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr110 Inhibitors

Olfactory Receptor 110 inhibitors, as considered in this context, encompass a diverse group of chemicals that indirectly modulate the function of Olfr110 by targeting various aspects of the olfactory signaling pathways. These inhibitors are not specific to Olfr110 but affect the broader signaling mechanisms that are crucial for the proper functioning of olfactory receptors in general. The first aspect of this inhibition strategy involves disrupting intracellular transport and signaling cascades. Compounds like Brefeldin A and Monensin interfere with protein transport and intracellular ion homeostasis, respectively. Such disruptions can impede the proper localization and function of olfactory receptors, including Olfr110. Similarly, inhibitors like Genistein and Forskolin target specific enzymatic activities-tyrosine kinases and adenylate cyclases-thereby influencing downstream signaling events crucial for receptor function.

The second aspect focuses on modulating second messengers and phosphorylation states, which are integral to olfactory receptor signaling. Compounds like KT5720, 2-APB, and U73122 specifically inhibit enzymes like protein kinase A, modulate calcium signaling, or inhibit phospholipase C activity. This modulation can have profound effects on the signal transduction processes associated with olfactory receptors. Furthermore, broad-spectrum inhibitors like Staurosporine offer an approach to globally affect kinase activities, potentially altering multiple pathways simultaneously. Overall, these inhibitors represent a comprehensive approach to modulating olfactory receptor signaling, albeit indirectly. By targeting key components of the signaling machinery, these chemicals provide insights into the complex network of interactions and processes that govern olfactory perception, including the function of Olfr110. While their effects are not exclusive to Olfr110, their influence on the olfactory system's broader signaling pathways makes them relevant to the study and modulation of this receptor.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$31.00
$53.00
$124.00
$374.00
25
(3)

Inhibits protein transport to Golgi, potentially disrupting OR transport and function.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$155.00
$525.00
(1)

Ionophore that disrupts intracellular pH and cation homeostasis, potentially affecting OR signaling.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$45.00
$164.00
$200.00
$402.00
$575.00
$981.00
$2031.00
46
(1)

Tyrosine kinase inhibitor, could indirectly affect OR signaling by altering kinase-mediated pathways.

KT 5720

108068-98-0sc-3538
sc-3538A
sc-3538B
50 µg
100 µg
500 µg
$138.00
$220.00
$972.00
47
(2)

PKA inhibitor, potentially alters phosphorylation states affecting OR function.

2-APB

524-95-8sc-201487
sc-201487A
20 mg
100 mg
$28.00
$53.00
37
(1)

Modulates intracellular Ca2+ signaling, possibly influencing OR-mediated pathways.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

MEK inhibitor, could indirectly affect OR signaling through the MAPK pathway.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

PI3K inhibitor, potentially alters OR signaling through phosphatidylinositol pathways.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Another PI3K inhibitor, offering an alternative approach to modulating OR signaling.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

General kinase inhibitor, may broadly affect phosphorylation events in OR signaling.

SK&F 96365

130495-35-1sc-201475
sc-201475B
sc-201475A
sc-201475C
5 mg
10 mg
25 mg
50 mg
$103.00
$158.00
$397.00
$656.00
2
(1)

TRPC channel blocker, potentially influencing calcium signaling in OR pathways.